

ASX ANNOUNCEMENT

ASTRA-ZENECA PRESENTATION

Sydney, Australia, 30 April 2014 Benitec Biopharma's CEO and Managing Director Dr Peter French has been invited by Astra-Zeneca Australia to present to a group of senior medical specialists in Adelaide on Wednesday evening, 30 April 2014. He will be presenting on two subjects: "The Art of Silencing Genes" and "ddRNAi- Now and into the future". This will be followed by a Q&A with the guests.

For further information, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company

Carl Stubbings
Chief Business Officer
Tel: +61 (2) 9555 6986
Email: cstubbings@benitec.com

Investor relations

Jane Lowe
Buchan Consulting
Tel: +61 (2) 9237 2807
Email: jlowe@buchanwe.com.au

About Benitec Biopharma Limited:

Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as Hepatitis C, Hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.